Baxter International (BAX) Research & Development (2009 - 2026)

Baxter International (BAX) has reported Research & Development for 18 consecutive years, with $129.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development fell 3.73% year-over-year to $129.0 million in Q2 2026; TTM through Jun 2026 was $542.0 million, a 14.59% increase from a year earlier, with the FY2025 full-year figure at $518.0 million, down 12.2% from the prior year.
• Research & Development was $129.0 million for Q2 2026 at Baxter International, down from $139.0 million in the prior quarter.
• Over five years, Research & Development peaked at $176.0 million in Q1 2024 and troughed at $2.0 million in Q4 2022.
• A 5-year average of $129.8 million and a median of $148.0 million in 2022 frame the typical range for Research & Development.
• Across the five-year window, Research & Development sank 98.52% in 2022 and soared 1050.0% in 2023, its largest moves.
• Over 5 years, Research & Development stood at $2.0 million in 2022, then soared by 1050.0% to $23.0 million in 2023, then soared by 665.22% to $176.0 million in 2024, then retreated by 23.86% to $134.0 million in 2025, then slipped by 3.73% to $129.0 million in 2026.
• The last three Research & Development figures came in at $129.0 million (Q2 2026), $139.0 million (Q1 2026), and $134.0 million (Q2 2025), per Business Quant data.